These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 16129848

  • 1. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM, National Wilms Tumor Study Group.
    J Clin Oncol; 2005 Oct 10; 23(29):7312-21. PubMed ID: 16129848
    [Abstract] [Full Text] [Related]

  • 2. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
    Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC.
    Cancer Res; 1994 May 01; 54(9):2331-3. PubMed ID: 8162576
    [Abstract] [Full Text] [Related]

  • 3. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G, Rieske P, Bartkowiak J, Szymik-Kantorowicz S, Daszkiewicz P, Debiec-Rychter M.
    Eur J Surg Oncol; 2000 Feb 01; 26(1):61-6. PubMed ID: 10718182
    [Abstract] [Full Text] [Related]

  • 4. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
    Fawzy M, Bahanassy A, Samir A, Hafez H.
    Pediatr Hematol Oncol; 2015 Feb 01; 32(8):548-56. PubMed ID: 26390800
    [Abstract] [Full Text] [Related]

  • 5. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P, Telzerow P, Moksness J, Breslow NE.
    Med Pediatr Oncol; 1996 Nov 01; 27(5):429-33. PubMed ID: 8926924
    [Abstract] [Full Text] [Related]

  • 6. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H, Semler O, Bürger D, Bode U, Flentje M, Göbel U, Gutjahr P, Leuschner I, Maass E, Niggli F, Scheel-Walter HG, Stöckle M, Thüroff JW, Tröger J, Weirich A, von Schweinitz D, Zoubek A, Graf N.
    Klin Padiatr; 2004 Nov 01; 216(3):132-40. PubMed ID: 15175957
    [Abstract] [Full Text] [Related]

  • 7. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
    Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, Grundy PE, Malogolowkin M, Beckwith JB, Shamberger RC, Haase GM, Coppes MJ, Coccia P, Kletzel M, Weetman RM, Donaldson M, Macklis RM, Green DM.
    J Clin Oncol; 2006 May 20; 24(15):2352-8. PubMed ID: 16710034
    [Abstract] [Full Text] [Related]

  • 8. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
    Fernandez CV, Mullen EA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE, Gow KW, Tochner Z, Hoffer FA, Withycombe JS, Shamberger RC, Kim Y, Geller JI, Anderson JR, Grundy PE, Dome JS.
    J Clin Oncol; 2018 Jan 20; 36(3):254-261. PubMed ID: 29211618
    [Abstract] [Full Text] [Related]

  • 9. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.
    Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M.
    Genes Chromosomes Cancer; 2007 Feb 20; 46(2):163-70. PubMed ID: 17099873
    [Abstract] [Full Text] [Related]

  • 10. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
    Mason JE, Goodfellow PJ, Grundy PE, Skinner MA.
    J Pediatr Surg; 2000 Jun 20; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
    [Abstract] [Full Text] [Related]

  • 11. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
    Park JE, Noh OK, Lee Y, Choi HS, Han JW, Hahn SM, Lyu CJ, Lee JW, Yoo KH, Koo HH, Jeong SY, Sung KW.
    Cancer Res Treat; 2020 Apr 20; 52(2):438-445. PubMed ID: 31505910
    [Abstract] [Full Text] [Related]

  • 12. Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Green DM, Breslow NE, Evans I, Moksness J, D'Angio GJ.
    Med Pediatr Oncol; 1996 Mar 20; 26(3):147-52. PubMed ID: 8544795
    [Abstract] [Full Text] [Related]

  • 13. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E, Li CM, Yamashiro DJ, Kandel J, Thaker H, Murty VV, Tycko B.
    Mol Cancer Res; 2005 Sep 20; 3(9):493-502. PubMed ID: 16179496
    [Abstract] [Full Text] [Related]

  • 14. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
    Messahel B, Williams R, Ridolfi A, A'hern R, Warren W, Tinworth L, Hobson R, Al-Saadi R, Whyman G, Brundler MA, Kelsey A, Sebire N, Jones C, Vujanic G, Pritchard-Jones K, Children's Cancer and Leukaemia Group (CCLG).
    Eur J Cancer; 2009 Mar 20; 45(5):819-26. PubMed ID: 19231157
    [Abstract] [Full Text] [Related]

  • 15. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD, Freemerman AJ, Langdon S, Bentley R, Goyeau D, Grundy PE, Skinner MA.
    J Pediatr Surg; 2005 Feb 20; 40(2):341-8. PubMed ID: 15750927
    [Abstract] [Full Text] [Related]

  • 16. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
    Evageliou N, Renfro LA, Geller J, Perlman E, Kalapurakal J, Paulino A, Dix D, Eklund MJ, Murphy AJ, Romao RLP, Ehrlich PF, Varela CR, Vallance K, Fernandez CV, Dome JS, Mullen EA.
    Cancer; 2024 Mar 01; 130(5):792-802. PubMed ID: 37902955
    [Abstract] [Full Text] [Related]

  • 17. Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology.
    Spreafico F, Gamba B, Mariani L, Collini P, D'Angelo P, Pession A, Di Cataldo A, Indolfi P, Nantron M, Terenziani M, Morosi C, Radice P, Perotti D, AIEOP Wilms Tumor Working Group.
    J Urol; 2013 Jan 01; 189(1):260-6. PubMed ID: 23174227
    [Abstract] [Full Text] [Related]

  • 18. Wilms' tumor at the Children's Hospital of Eastern Ontario: 1990-2001.
    Pianezza ML, Rubin S, Bass J, Chou S, Pike JG, Leonard MP.
    Can J Urol; 2004 Feb 01; 11(1):2151-6. PubMed ID: 15003157
    [Abstract] [Full Text] [Related]

  • 19. Chromosome arm 16q in Wilms tumors: unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene.
    Yeh A, Wei M, Golub SB, Yamashiro DJ, Murty VV, Tycko B.
    Genes Chromosomes Cancer; 2002 Oct 01; 35(2):156-63. PubMed ID: 12203779
    [Abstract] [Full Text] [Related]

  • 20. Clinical, pathological and loss of heterozygosity differences in Wilms tumors between Asian and non-Asian children.
    Loke BN, Wong MK, Tawng KD, Kuick CH, Jain S, Lian D, Wagner E, Zou Y, Ganesan V, Sim SW, Lee YT, Chin F, Chan MY, Tan AM, Teh BT, Soh SY, Chang KTE, Loh AHP.
    Int J Cancer; 2019 Mar 15; 144(6):1234-1242. PubMed ID: 30362502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.